Gastrinoma

Imamura, Masayuki; Komoto, Izumi

doi:10.1007/978-1-84628-881-4_38

Cited by 4 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Differential Diagnosis Of Functioning Pd‐netmentioning

confidence: 99%

“…The SASI test can locate both the area where functioning PD‐NET exists and also the area where functioning PD‐NET does not exist . So, a surgeon can confidently perform surgery for curative resection of PD‐NET . As the patients with MEN 1 have a number of P‐NETs, differentiation of insulinoma or gastrinoma is impossible only with imaging techniques, and only the SASI test can indicate which ones are functioning PD‐NET, because its diagnostic principle is based on the hormone secretion from a functioning PD‐NET .…”

Section: Differential Diagnosis Of Functioning Pd‐netmentioning

confidence: 99%

“…Before 1990, doctors had thought that ZES was caused mostly by a large pancreatic gastrinoma, although Oberhelman et al had reported a few cases of duodenal gastrinoma as a cause of ZES in 1962 . Since the resection of gastrinoma in patients with ZES guided by the SASI test started , it has been revealed that the resection of duodenal gastrinoma has cured ZES . Now, duodenal gastrinoma has been found in more than 60% of patients with sporadic ZES and in more than 80% of patients with MEN 1 and ZES .…”

Section: Insulinomamentioning

confidence: 99%

“…Functioning pancreaticoduodenal neuroendocrine tumors (PD‐NETs) have attracted a number of scientific surgeons for their mysterious features . It has taken time for clinicians to understand that a tiny NET, which is often difficult to detect only by imaging techniques, is the cause of several severe clinical symptoms . Almost 50 years passed before it was learned that most cases of the Zollinger‐Ellison syndrome are often caused by a tiny duodenal gastrinoma rather than a large pancreatic gastrinoma .…”

Section: Introductionmentioning

confidence: 99%

“…It has taken time for clinicians to understand that a tiny NET, which is often difficult to detect only by imaging techniques, is the cause of several severe clinical symptoms . Almost 50 years passed before it was learned that most cases of the Zollinger‐Ellison syndrome are often caused by a tiny duodenal gastrinoma rather than a large pancreatic gastrinoma . Clinical science of functioning PD‐NET has promoted the progress of both basic gastrointestinal hormone science, and vice versa .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors

Imamura

Nakamoto

Uose

et al. 2015

J Hepato Biliary Pancreat

Self Cite

View full text Add to dashboard Cite

Functioning pancreaticoduodenal neuroendocrine tumors (PD-NETs) are popular in a textbook, but they are still unfamiliar to a general clinician, and delay of diagnosis or misdiagnosis has been reported even today. It is a consensus that sporadic functioning PD-NET is cured only by surgical resection. So, early detection and early resection is the gold standard for the treatment of functioning PD-NET. Functioning PD-NETs in patients with multiple endocrine neoplasia type 1 (MEN 1) are often multiple. You should check about MEN 1 whenever you encountered multiple PD-NET. They are diagnosed in younger age than sporadic cases. In most cases they are accompanied with numerous microscopic or macroscopic nonfunctioning P-NETs, which are potentially metastatic and the most common cause of death in MEN 1 patients.

show abstract

Section: Differential Diagnosis Of Functioning Pd‐netmentioning

confidence: 99%

Section: Differential Diagnosis Of Functioning Pd‐netmentioning

confidence: 99%

Section: Insulinomamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors

Imamura

Nakamoto

Uose

et al. 2015

J Hepato Biliary Pancreat

Self Cite

View full text Add to dashboard Cite

show abstract

Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1

Hanazaki

Sakurai²,

Munekage

et al. 2012

Surg Today

View full text Add to dashboard Cite

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited endocrine tumor syndrome characterized by tumor development in various endocrine organs such as the parathyroid, endocrine pancreas, anterior pituitary and adrenal cortex. The first extensive database for Asian patients with MEN1 was established by the MEN Consortium of Japan. Although the clinical features of Japanese patients with MEN1 are similar to those from Western countries, there are several characteristic differences between them. In particular, gastroenteropancreatic neuroendocrine tumor (GEPNET) is seen in approximately 60 % of patients with MEN1 in Japan. Although its development is the strongest prognostic factor in patients with MEN1, the characteristics of MEN1-associated GEPNET still remain unclear. This is especially true for the differences in clinical features of GEPNET with and without MEN1. Improved long-term survival is obtained by curative surgery for patients with MEN1-associated GEPNET. The current surgical indications are expanding even in patients with hepatic metastases because of the improved surgical outcome. This article reviews the clinical characteristics in these patients with a particular focus on surgery, diagnosis, surgical indications, surgical method, and surgical outcome.

show abstract

Management of neuroendocrine tumors of unknown primary

Alexandraki

Angelousi

Boutzios

et al. 2017

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Neuroendocrine neoplams (NENs) are mostly relatively indolent malignancies but a significant number have metastatic disease at diagnosis mainly to the liver. Although in the majority of such cases the primary origin of the tumor can be identified, in approximately 11-22% no primary tumor is found and such cases are designated as NENs of unknown primary origin (UPO). This has significant therapeutic implications with respect to potentially resectable hepatic disease and/or application of appropriate medical therapy, either chemotherapeutic agents or targeted treatment, as the response to various treatments varies according to the origin of the primary tumor. This lack of tumor specific orientated treatment may also account for the relatively poorer prognosis of NENs of UPO compared to metastatic NENs with a known primary site. In the majority of cases the primary tumors are located in the small bowel and the lung, but a number may still elude detection. Occasionally the presence of a functional syndrome may direct to the specific tissue of origin but in the majority of cases a number of biochemical, imaging, histopathological and molecular modalities are utilized to help identify the primary origin of the tumor and direct treatment accordingly. Several diagnostic algorithms have recently been developed to help localize an occult primary tumor; however, in a number of cases no lesion is identified even after prolonged follow-up. It is expected that the delineation of the molecular signature of the different NENs may help identify such cases and provide appropriate treatment.

show abstract

Gastrinoma

Cited by 4 publications

References 54 publications

Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors

Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors

Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1

Management of neuroendocrine tumors of unknown primary

Contact Info

Product

Resources

About